Related Experiment Video
Updated: Aug 11, 2026

Quantitative In vitro Assay to Measure Neutrophil Adhesion to Activated Primary Human Microvascular Endothelial Cells under Static Conditions
Published on: August 23, 2013
Canine neutrophil margination mediated by lectin adhesion molecule-1 in vitro
O Abbassi1, C L Lane, S Krater
1Biomedical Engineering Laboratory, Rice University, Houston, TX 77251.
Insights
Canine neutrophil lectin adhesion molecule-1 (LECAM-1) aids initial neutrophil adhesion to endothelial cells under flow. However, LECAM-1 does not influence neutrophil transendothelial migration, unlike CD18-integrins.
Area of Science:
- Immunology
- Cell Biology
- Vascular Biology
Background:
- Neutrophil adhesion and migration are critical for inflammatory responses.
- Leukocyte adhesion molecules, such as LECAM-1 and CD18-integrins, mediate these processes.
- The specific roles of canine LECAM-1 in neutrophil-endothelial interactions under flow remain incompletely understood.
Purpose of the Study:
- To investigate the function of canine neutrophil LECAM-1 in neutrophil-endothelial cell adhesion.
- To determine the role of canine LECAM-1 in transendothelial migration of neutrophils.
- To compare the contributions of LECAM-1 and CD18-integrins under varying shear stress conditions.
Main Methods:
- Utilized anti-LECAM-1 monoclonal antibodies (mAbs) CL2/6 and SL1, and anti-CD18 mAb R15.7.
- Assessed neutrophil adhesion to cytokine-stimulated canine jugular vein endothelium under static and flow conditions (up to 1.85 dynes/cm²).
- Evaluated transendothelial migration of adherent neutrophils.
Main Results:
- Anti-LECAM-1 mAbs inhibited neutrophil attachment, with greater effect at higher shear stress (1.85 dpc).
- Anti-CD18 mAb showed higher inhibition at lower shear stress and static conditions, with minimal effect at 1.85 dpc.
- Chemotactic stimulation reduced LECAM-1 surface expression and adhesion, while anti-CD18 mAb significantly blocked transendothelial migration.
Conclusions:
- Canine LECAM-1 mediates initial adhesion of unstimulated neutrophils to activated endothelium under flow.
- Unlike CD18-integrins, LECAM-1 does not play a role in transendothelial migration.
- LECAM-1 and CD18-integrins have distinct, partially additive roles in neutrophil adhesion under low shear stress.
Abstract:
The contributions of the canine neutrophil lectin adhesion molecule-1 (LECAM-1) (canine homologue of the murine MEL-14 Ag) in neutrophil-endothelial cell adhesion and transendothelial migration were studied using anti-LECAM-1 mAb, CL2/6, and SL1 under static conditions and at wall shear stresses of up to 1.85 dynes/cm2 (dpc). Both mAb were found to inhibit attachment of neutrophils to cytokine-stimulated canine jugular vein endothelium. The inhibitory effects of the anti-LECAM-1 mAb were more evident at a wall shear stress of 1.85 dpc (greater than 50%) than at 0.23 dpc or under static conditions (approximately 30%). In contrast the anti-CD18 mAb, R15.7, exhibited higher inhibitory ability at the lower shear stress and under static conditions with marginal inhibition of adhesion at 1.85 dpc. Anti-LECAM-1 and anti-CD18 mAb showed additive inhibitory effects at the lower wall shear stress and under static conditions. Chemotactic stimulation of the neutrophils caused rapid down-regulation of LECAM-1 from the neutrophil surface and reduced adhesion by 60% at a wall shear stress of 1.85 dpc. This inhibition was not additive to anti-LECAM-1 mAb. Pretreatment with CL2/6 or SL1 did not affect trans-endothelial migration of adherent neutrophils under any experimental conditions tested. Anti-CD18 mAb, however, blocked transendothelial migration by 98% and 56% under static condition and at a wall shear stress of 0.23 dpc, respectively. The results in this report indicate that canine LECAM-1 is involved in the initial adhesion of unstimulated neutrophils to cytokine-stimulated endothelial cells under flow, but in contrast to CD18-integrins, plays no role in the transendothelial migration.
Related Concept Videos
Selectins
Acute Inflammation II: Cellular Phase

